DBV Technologies
| Use attributes for filter ! | |
| Stock price | DBV |
|---|---|
| Disclaimer | |
| Headquarters | Montrouge |
| France | |
| Founded | Bagneux |
| France | |
| Chief commercial officer | Kevin Trapp |
| Chief scientific officer | H a Sampson |
| Founders | Bertrand Dupont |
| Christophe Dupont | |
| Pierre-Henri Benhamou | |
| Subsidiary | DBV Technologies Inc. |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2447275 |
About DBV Technologies
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood.
